Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID

Claire Booth1,2, H Bobby Gaspar1,21Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK; 2Dept of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UKAbstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine...

Full description

Bibliographic Details
Main Authors: Claire Booth, H Bobby Gaspar
Format: Article
Language:English
Published: Dove Medical Press 2009-06-01
Series:Biologics : Targets & Therapy
Online Access:http://www.dovepress.com/pegademase-bovine-peg-ada-for-the-treatment-of-infants-and-children-wi-a3286
id doaj-951c4df78fd143a5b421a262ed2ac31b
record_format Article
spelling doaj-951c4df78fd143a5b421a262ed2ac31b2020-11-24T22:32:02ZengDove Medical PressBiologics : Targets & Therapy1177-54751177-54912009-06-012009default349358Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCIDClaire BoothH Bobby GasparClaire Booth1,2, H Bobby Gaspar1,21Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK; 2Dept of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UKAbstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine metabolism characterized by immunodeficiency, failure to thrive and metabolic abnormalities. A lack of the enzyme ADA allows accumulation of toxic metabolites causing defects of both cell mediated and humoral immunity leading to ADA severe combined immune deficiency (SCID), a condition that can be fatal in early infancy if left untreated. Hematopoietic stem cell transplant is curative but is dependent on a good donor match. Other therapeutic options include enzyme replacement therapy (ERT) with pegademase bovine (PEG-ADA) and more recently gene therapy. PEG-ADA has been used in over 150 patients worldwide and has allowed stabilization of patients awaiting more definitive treatment with hematopoietic stem cell transplant. It affords both metabolic detoxification and protective immune function with patients remaining clinically well, but immune reconstitution is often suboptimal and may not be long lived. We discuss the pharmacokinetics, immune reconstitution, effects on systemic disease and side effects of treatment with PEG-ADA. We also review the long-term outcome of patients receiving ERT and discuss the role of PEG-ADA in the management of infants and children with ADA-SCID, alongside other therapeutic options.Keywords: adenosine deaminase deficiency, PEG-ADA, enzyme replacement therapy, severe combined immune deficiency (SCID) http://www.dovepress.com/pegademase-bovine-peg-ada-for-the-treatment-of-infants-and-children-wi-a3286
collection DOAJ
language English
format Article
sources DOAJ
author Claire Booth
H Bobby Gaspar
spellingShingle Claire Booth
H Bobby Gaspar
Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Biologics : Targets & Therapy
author_facet Claire Booth
H Bobby Gaspar
author_sort Claire Booth
title Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
title_short Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
title_full Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
title_fullStr Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
title_full_unstemmed Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
title_sort pegademase bovine (peg-ada) for the treatment of infants and children with severe combined immunodeficiency (scid
publisher Dove Medical Press
series Biologics : Targets & Therapy
issn 1177-5475
1177-5491
publishDate 2009-06-01
description Claire Booth1,2, H Bobby Gaspar1,21Centre for Immunodeficiency, Molecular Immunology Unit, UCL Institute of Child Health, London, UK; 2Dept of Clinical Immunology, Great Ormond Street Hospital NHS Trust, London, UKAbstract: Adenosine deaminase deficiency (ADA) is a rare, inherited disorder of purine metabolism characterized by immunodeficiency, failure to thrive and metabolic abnormalities. A lack of the enzyme ADA allows accumulation of toxic metabolites causing defects of both cell mediated and humoral immunity leading to ADA severe combined immune deficiency (SCID), a condition that can be fatal in early infancy if left untreated. Hematopoietic stem cell transplant is curative but is dependent on a good donor match. Other therapeutic options include enzyme replacement therapy (ERT) with pegademase bovine (PEG-ADA) and more recently gene therapy. PEG-ADA has been used in over 150 patients worldwide and has allowed stabilization of patients awaiting more definitive treatment with hematopoietic stem cell transplant. It affords both metabolic detoxification and protective immune function with patients remaining clinically well, but immune reconstitution is often suboptimal and may not be long lived. We discuss the pharmacokinetics, immune reconstitution, effects on systemic disease and side effects of treatment with PEG-ADA. We also review the long-term outcome of patients receiving ERT and discuss the role of PEG-ADA in the management of infants and children with ADA-SCID, alongside other therapeutic options.Keywords: adenosine deaminase deficiency, PEG-ADA, enzyme replacement therapy, severe combined immune deficiency (SCID)
url http://www.dovepress.com/pegademase-bovine-peg-ada-for-the-treatment-of-infants-and-children-wi-a3286
work_keys_str_mv AT clairebooth pegademasebovinepegadaforthetreatmentofinfantsandchildrenwithseverecombinedimmunodeficiencyscid
AT hbobbygaspar pegademasebovinepegadaforthetreatmentofinfantsandchildrenwithseverecombinedimmunodeficiencyscid
_version_ 1725735443782172672